Drug project high-priority medications: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 24: Line 24:
===Novel Drug Approvals for 2020===
===Novel Drug Approvals for 2020===


 
{| class="wikitable"
! No. !! Drug Name !! Active Ingredient !! Approval Date !! FDA-approved use on approval date
|-
| 53 || Gemtesa || vibegron || 12/23/2020 || To treat overactive bladder
|-
| 52 || Ebanga || ansuvimab-zykl || 12/21/2020 || To treat ebola
|-
| 51 || Orgovyx || relugolix || 12/18/2020 || To treat advanced prostate cancer
|-
| 50 || Margenza || margetuximab (anti-HER2 mAb || 12/16/2020 || To treat HER2+ breast cancer
|-
| 49 || Klisyri || tirbanibulin || 12/14/2020 || To treat actinic Keratosis of the face or scalp
|-
| 48 || Orladeyo || berotralstat || 12/3/2020 || To treat patients with hereditary angioedema
|-
| 47 || Gallium 68 PSMA-11 || Gallium 68 PSMA-11 || 12/1/2020 || For detection and localization of prostate cancer
|-
| 46 || Danyelza || naxitamab-gqgk || 11/25/2020 || To treat high-risk refractory or relapsed neuroblastoma
|-
| 45 || Imcivree || setmelanotide || 11/25/2020 || To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age
|-
| 44 || Oxlumo || lumasiran || 11/23/2020 || To treat hyperoxaluria type 1
|-
| 43 || Zokinvy || lonafarnib || 11/20/2020 || To treat rare conditions related to premature aging
|-
| 42 || Veklury || remdesivir || 10/22/2020 || To treat COVID-19
|-
| 41 || Inmazeb || atoltivimab, maftivimab, and odesivimab-ebgn || 10/14/2020 || To treat ebola virus
|-
| 40 || Gavreto || pralsetinib || 9/4/2020 || To treat non-small lung cancer
|-
| 39 || Detectnet || copper Cu 64 dotatate injection || 9/3/2020 || To help detect certain types of neuroendocrine tumors
|-
| 38 || Sogroya || somapacitan-beco || 8/28/2020 || Growth hormone
|-
| 37 || Winlevi || clascoterone || 8/26/2020 || To treat acne
|-
| 36 || Enspryng || satralizumab-mwge || 8/14/2020 || To treat neuromyelitis optica spectrum disorder
|-
| 35 || Viltepso || viltolarsen || 8/12/2020 || To treat Duchenne muscular dystrophy
|-
| 34 || Olinvyk || oliceridine || 8/7/2020 || To manage acute pain in certain adults
|-
| 33 || Evrysdi || risdiplam || 8/7/2020 || To treat spinal muscular atrophy
|-
| 32 || Lampit || nifurtimox || 8/6/2020 || To treat Chagas disease in certain pediatric patients younger than age 18
|-
| 31 || Blenrep || belantamab mafodotin-blmf || 8/5/2020 || To treat multiple myeloma
|-
| 30 || Monjuvi || tafasitamab-cxix || 7/31/2020 || To treat relapsed or refractory diffuse large B-cell lymphoma
|-
| 29 || Xeglyze || abametapir || 7/24/2020 || To treat head lice
|-
| 28 || Inqovi || decitabine and cedazuridine || 7/7/2020 || To treat adult patients with myelodysplastic syndromes
|-
| 27 || Rukobia || fostemsavir || 7/2/2020 || To treat HIV
|-
| 26 || Byfavo || remimazolam || 7/2/2020 || For sedation
|-
| 25 || Dojolvi || triheptanoin || 6/30/2020 || To treat molecularly long-chain fatty acid oxidation disorders
|-
| 24 || Zepzelca || lurbinectedin || 6/15/2020 || To treat metastatic small cell lung cancer
|-
| 23 || Uplizna || inebilizumab-cdon || 6/11/2020 || To treat neuromyelitis optica spectrum disorder
|-
| 22 || Tauvid || flortaucipir F18 || 5/28/2020 || Diagnostic agent for patients with Alzheimer’s disease
|-
| 21 || Artesunate || artesunate || 5/26/2020 || To treat severe malaria
|-
| 20 || Cerianna || fluoroestradiol F18 || 5/20/2020 || Diagnostic imaging agent for certain patients with breast cancer
|-
| 19 || Qinlock || ripretinib || 5/15/2020 || To treat advanced gastrointestinal-stromal tumors
|-
| 18 || Retevmo || selpercatinib || 5/8/2020 || To treat lung and thyroid cancers
|-
| 17 || Tabrecta || capmatinib || 5/6/2020 || To treat patients with non small cell lung cancer
|-
| 16 || Ongentys || opicapone || 4/24/2020 || To treat patients with Parkinson’s disease experiencing “off” episodes
|-
| 15 || Trodelvy || sacituzumab govitecan-hziy || 4/22/2020 || To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease
|-
| 14 || Pemazyre || pemigatinib || 4/17/2020 || To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts
|-
| 13 || Tukysa || tucatinib || 4/17/2020 || To treat advanced unresectable or metastatic HER2-positive breast cancer
|-
| 12 || Koselugo || selumetinib || 4/10/2020 || To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves
|-
| 11 || Zeposia || ozanimod || 3/25/2020 || To treat relapsing forms of multiple sclerosis
|-
| 10 || Isturisa || osilodrostat || 3/6/2020 || To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease
|-
| 9 || Sarclisa || isatuximab || 3/2/2020 || To treat multiple myloma
|-
| 8 || Nurtec ODT || rimegepant || 2/27/2020 || To treat migraine
|-
| 7 || Barhemsys || amisulpride || 2/26/2020 || To help prevent nausea and vomiting after surgery
|-
| 6 || Vyepti || eptinezumab-jjmr || 2/21/2020 || For the preventive treatment of migraine in adults
|-
| 5 || Nexletol || bempedoic acid || 2/21/2020 || To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C
|-
| 4 || Pizensy || lactitol || 2/12/2020 || To treat chronic idiopathic constipation (CIC) in adults
|-
| 3 || Tazverik || tazemetostat || 1/23/2020 || To treat epithelioid sarcoma
|-
| 2 || Tepezza || teprotumumab-trbw || 1/21/2020 || To treat Thyroid eye disease
|-
| 1 || Ayvakit || avapritinib || 1/9/2020 || To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST)
|}


===Novel Drug Approvals for 2019===
===Novel Drug Approvals for 2019===
Line 128: Line 236:
|}
|}


 
<!---
 
 
{| class="wikitable"
{| class="wikitable"
| align="center" style="background:#f0f0f0;" |'''Year'''
| align="center" style="background:#f0f0f0;" |'''Year'''
Line 426: Line 532:
|
|
|}
|}
--->
</div>
</div>

Revision as of 22:07, 11 November 2021

   Mission Statement   
   Tutorial   
   Editor's Checklist   

WikiDoc Drug Project — High-Priority Medications

List of high-priority medications

Novel Drug Approvals for 2021

Novel Drug Approvals for 2020

No. Drug Name Active Ingredient Approval Date FDA-approved use on approval date
53 Gemtesa vibegron 12/23/2020 To treat overactive bladder
52 Ebanga ansuvimab-zykl 12/21/2020 To treat ebola
51 Orgovyx relugolix 12/18/2020 To treat advanced prostate cancer
50 Margenza margetuximab (anti-HER2 mAb 12/16/2020 To treat HER2+ breast cancer
49 Klisyri tirbanibulin 12/14/2020 To treat actinic Keratosis of the face or scalp
48 Orladeyo berotralstat 12/3/2020 To treat patients with hereditary angioedema
47 Gallium 68 PSMA-11 Gallium 68 PSMA-11 12/1/2020 For detection and localization of prostate cancer
46 Danyelza naxitamab-gqgk 11/25/2020 To treat high-risk refractory or relapsed neuroblastoma
45 Imcivree setmelanotide 11/25/2020 To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age
44 Oxlumo lumasiran 11/23/2020 To treat hyperoxaluria type 1
43 Zokinvy lonafarnib 11/20/2020 To treat rare conditions related to premature aging
42 Veklury remdesivir 10/22/2020 To treat COVID-19
41 Inmazeb atoltivimab, maftivimab, and odesivimab-ebgn 10/14/2020 To treat ebola virus
40 Gavreto pralsetinib 9/4/2020 To treat non-small lung cancer
39 Detectnet copper Cu 64 dotatate injection 9/3/2020 To help detect certain types of neuroendocrine tumors
38 Sogroya somapacitan-beco 8/28/2020 Growth hormone
37 Winlevi clascoterone 8/26/2020 To treat acne
36 Enspryng satralizumab-mwge 8/14/2020 To treat neuromyelitis optica spectrum disorder
35 Viltepso viltolarsen 8/12/2020 To treat Duchenne muscular dystrophy
34 Olinvyk oliceridine 8/7/2020 To manage acute pain in certain adults
33 Evrysdi risdiplam 8/7/2020 To treat spinal muscular atrophy
32 Lampit nifurtimox 8/6/2020 To treat Chagas disease in certain pediatric patients younger than age 18
31 Blenrep belantamab mafodotin-blmf 8/5/2020 To treat multiple myeloma
30 Monjuvi tafasitamab-cxix 7/31/2020 To treat relapsed or refractory diffuse large B-cell lymphoma
29 Xeglyze abametapir 7/24/2020 To treat head lice
28 Inqovi decitabine and cedazuridine 7/7/2020 To treat adult patients with myelodysplastic syndromes
27 Rukobia fostemsavir 7/2/2020 To treat HIV
26 Byfavo remimazolam 7/2/2020 For sedation
25 Dojolvi triheptanoin 6/30/2020 To treat molecularly long-chain fatty acid oxidation disorders
24 Zepzelca lurbinectedin 6/15/2020 To treat metastatic small cell lung cancer
23 Uplizna inebilizumab-cdon 6/11/2020 To treat neuromyelitis optica spectrum disorder
22 Tauvid flortaucipir F18 5/28/2020 Diagnostic agent for patients with Alzheimer’s disease
21 Artesunate artesunate 5/26/2020 To treat severe malaria
20 Cerianna fluoroestradiol F18 5/20/2020 Diagnostic imaging agent for certain patients with breast cancer
19 Qinlock ripretinib 5/15/2020 To treat advanced gastrointestinal-stromal tumors
18 Retevmo selpercatinib 5/8/2020 To treat lung and thyroid cancers
17 Tabrecta capmatinib 5/6/2020 To treat patients with non small cell lung cancer
16 Ongentys opicapone 4/24/2020 To treat patients with Parkinson’s disease experiencing “off” episodes
15 Trodelvy sacituzumab govitecan-hziy 4/22/2020 To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease
14 Pemazyre pemigatinib 4/17/2020 To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts
13 Tukysa tucatinib 4/17/2020 To treat advanced unresectable or metastatic HER2-positive breast cancer
12 Koselugo selumetinib 4/10/2020 To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves
11 Zeposia ozanimod 3/25/2020 To treat relapsing forms of multiple sclerosis
10 Isturisa osilodrostat 3/6/2020 To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease
9 Sarclisa isatuximab 3/2/2020 To treat multiple myloma
8 Nurtec ODT rimegepant 2/27/2020 To treat migraine
7 Barhemsys amisulpride 2/26/2020 To help prevent nausea and vomiting after surgery
6 Vyepti eptinezumab-jjmr 2/21/2020 For the preventive treatment of migraine in adults
5 Nexletol bempedoic acid 2/21/2020 To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C
4 Pizensy lactitol 2/12/2020 To treat chronic idiopathic constipation (CIC) in adults
3 Tazverik tazemetostat 1/23/2020 To treat epithelioid sarcoma
2 Tepezza teprotumumab-trbw 1/21/2020 To treat Thyroid eye disease
1 Ayvakit avapritinib 1/9/2020 To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST)

Novel Drug Approvals for 2019

No. Drug Name Active Ingredient Approval Date FDA-approved use on approval date
48 Ubrelvy ubrogepant 12/23/2019 to treat acute treatment of migraine with or without aura in adults
47 Enhertu fam-trastuzumab deruxtecan-nxki 12/20/2019 To treat metastatic breast cancer
46 Dayvigo lemborexant 12/20/2019 To treat insomnia
45 Caplyta lumateperone tosylate 12/20/2019 To treat schizophrenia
44 TissueBlue Brilliant Blue G Ophthalmic Solution 12/20/2019 Dye used in eye surgery
43 Padcev enfortumab vedotin-ejfv 12/18/2019 To treat refractory bladder cancer
42 Vyondys 53 golodirsen 12/12/2019 To treat certain patients with Duchenne muscular dystrophy
41 Oxbryta voxelotor 11/25/2019 To treat sickle cell disease
40 Xcopri cenobamate 11/21/2019 To treat partial onset seizures
39 Givlaari givosiran 11/20/2019 To treat acute hepatic porphyria, a rare blood disorder
38 Adakveo crizanlizumab-tmca 11/15/2019 To treat patients with painful complication of sickle cell disease
37 Fetroja cefiderocol 11/14/2019 To treat patients with complicated urinary tract infections who have limited or no alternative treatment options
36 Brukinsa zanubrutinib 11/14/2019 To treat certain patients with mantle cell lymphoma, a form of blood cancer
35 Reblozyl luspatercept–aamt 11/8/2019 For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions
34 ExEm Foam air polymer-type A 11/7/2019 A diagnostic agent used to assess fallopian tube patency (openness) in women with known or suspected infertility
33 Trikafta elexacaftor/ivacaftor/tezacaftor 10/21/2019 To treat patients 12 years of age and older with the most common gene mutation that causes cystic fibrosis
32 Reyvow lasmiditan 10/11/2019 For the acute treatment of migraine with or without aura, in adults
31 fluorodopa F 18 10/10/2019 A diagnostic agent for use in positron emission tomography (PET) to help diagnose adult patients with suspected Parkinsonian syndromes (PS)
30 Scenesse afamelanotide 10/8/2019 To increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria
29 Beovu brolucizumab–dbll 10/7/2019 Treatment of wet age-related macular degeneration
28 Aklief trifarotene 10/4/2019 For the topical treatment of acne vulgaris in patients 9 years of age and older
27 Ibsrela tenapanor 9/12/2019 To treat irritable bowel syndrome with constipation in adults.
26 Nourianz istradefylline 8/27/2019 To treat adult patients with Parkinson’s disease experiencing “off” episodes
25 Ga-68-DOTATOC Ga-68-DOTATOC 8/21/2019 For use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs)
24 Xenleta lefamulin 8/19/2019 To treat adults with community-acquired bacterial pneumonia
23 Rinvoq upadacitinib 8/16/2019 To treat adults with moderately to severely active rheumatoid arthritis
22 Inrebic fedratinib 8/16/2019 To treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
21 Rozlytrek entrectinib 8/15/2019 To treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive
20 Wakix pitolisant 8/14/2019 To treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy
19 pretomanid 8/14/2019 For treatment-resistant forms of tuberculosis that affects the lungs
18 Turalio pexidartinib 8/2/2019 To treat adult patients with symptomatic tenosynovial giant cell tumor
17 Nubeqa darolutamide 7/30/2019 To treat adult patients with non-metastatic castration resistant prostate cancer
16 Accrufer ferric maltol 7/25/2019 To treat iron deficiency anemia in adults
15 Recarbrio imipenem, cilastatin and relebactam 7/16/2019 To treat complicated urinary tract and complicated intra-abdominal infections
14 Xpovio selinexor 7/3/2019 To treat adult patients with relapsed or refractory multiple myeloma (RRMM)
13 Vyleesi bremelanotide 6/21/2018 To treat hypoactive sexual desire disorder in premenopausal women.
12 Polivy polatuzumab vedotin-piiq 6/10/2019 To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma
11 Piqray alpelisib 5/24/2019 To treat breast cancer
10 Vyndaqel tafamidis meglumine 5/3/2019 To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults
9 Skyrizi risankizumab-rzaa 4/23/2019 To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
8 Balversa erdafitinib 4/12/2019 To treat adult patients with locally advanced or metastatic bladder cancer
7 Evenity romosozumab-aqqg 4/9/2019 To treat osteoporosis in postmenopausal women at high risk of fracture
6 Mayzent siponimod 3/26/2019 To treat adults with relapsing forms of multiple sclerosis
5 Sunosi solriamfetol 3/20/2019 To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
4 Zulresso brexanolone 3/19/2019 To treat postpartum depression (PPD) in adult women
3 Egaten triclabendazole 2/13/2019 To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”
2 Cablivi caplacizumab-yhdp 2/6/2019 To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP)
1 Jeuveau prabotulinumtoxinA-xvfs 2/1/2019 For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients
Retrieved from "https://www.wikidoc.org/index.php?title=Drug_project_high-priority_medications&oldid=1716457"